Taiwan
· Delayed Price · Currency is TWD TaiMed Biologics Statistics
Total Valuation
TaiMed Biologics has a market cap or net worth of TWD 21.76 billion. The enterprise value is 20.11 billion.
| Market Cap | 21.76B |
| Enterprise Value | 20.11B |
Important Dates
The last earnings date was Tuesday, November 12, 2024.
| Earnings Date | Nov 12, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
TaiMed Biologics has 273.01 million shares outstanding. The number of shares has increased by 2.30% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 273.01M |
| Shares Change (YoY) | +2.30% |
| Shares Change (QoQ) | -1.16% |
| Owned by Insiders (%) | 1.45% |
| Owned by Institutions (%) | 5.31% |
| Float | 185.53M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 33.19 |
| PB Ratio | 5.19 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 147.47 |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -142.00 |
| EV / Sales | 32.30 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | 136.32 |
Financial Position
The company has a current ratio of 5.66, with a Debt / Equity ratio of 0.13.
| Current Ratio | 5.66 |
| Quick Ratio | 3.20 |
| Debt / Equity | 0.13 |
| Debt / EBITDA | n/a |
| Debt / FCF | 3.59 |
| Interest Coverage | -11.37 |
Financial Efficiency
Return on equity (ROE) is -4.17% and return on invested capital (ROIC) is -2.32%.
| Return on Equity (ROE) | -4.17% |
| Return on Assets (ROA) | -1.93% |
| Return on Capital (ROIC) | -2.32% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.13 |
| Inventory Turnover | 0.28 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -4.61% in the last 52 weeks. The beta is 0.32, so TaiMed Biologics's price volatility has been lower than the market average.
| Beta (5Y) | 0.32 |
| 52-Week Price Change | -4.61% |
| 50-Day Moving Average | 79.50 |
| 200-Day Moving Average | 85.89 |
| Relative Strength Index (RSI) | 45.15 |
| Average Volume (20 Days) | 527,240 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, TaiMed Biologics had revenue of TWD 622.61 million and -141.65 million in losses. Loss per share was -0.55.
| Revenue | 622.61M |
| Gross Profit | 270.63M |
| Operating Income | -150.22M |
| Pretax Income | -141.65M |
| Net Income | -141.65M |
| EBITDA | -2.38M |
| EBIT | -150.22M |
| Loss Per Share | -0.55 |
Balance Sheet
The company has 2.18 billion in cash and 529.91 million in debt, giving a net cash position of 1.65 billion or 6.03 per share.
| Cash & Cash Equivalents | 2.18B |
| Total Debt | 529.91M |
| Net Cash | 1.65B |
| Net Cash Per Share | 6.03 |
| Equity (Book Value) | 4.15B |
| Book Value Per Share | 15.37 |
| Working Capital | 3.37B |
Cash Flow
In the last 12 months, operating cash flow was 156.74 million and capital expenditures -9.19 million, giving a free cash flow of 147.55 million.
| Operating Cash Flow | 156.74M |
| Capital Expenditures | -9.19M |
| Free Cash Flow | 147.55M |
| FCF Per Share | 0.54 |
Margins
Gross margin is 43.47%, with operating and profit margins of -24.13% and -22.75%.
| Gross Margin | 43.47% |
| Operating Margin | -24.13% |
| Pretax Margin | -22.75% |
| Profit Margin | -22.75% |
| EBITDA Margin | -0.38% |
| EBIT Margin | -24.13% |
| FCF Margin | 23.70% |
Dividends & Yields
TaiMed Biologics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -2.30% |
| Shareholder Yield | -2.30% |
| Earnings Yield | -0.69% |
| FCF Yield | 0.68% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | n/a |